Your browser is no longer supported. Please, upgrade your browser.
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own4.20% Shs Outstand39.95M Perf Week27.69%
Market Cap2.41B Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float37.42M Perf Month-23.40%
Income-12.70M PEG- EPS next Q-0.16 Inst Own28.00% Short Float23.73% Perf Quarter-21.00%
Sales- P/S- EPS this Y8.80% Inst Trans1.55% Short Ratio1.12 Perf Half Y33.00%
Book/sh6.92 P/B8.95 EPS next Y25.40% ROA-7.40% Target Price- Perf Year537.90%
Cash/sh7.17 P/C8.64 EPS next 5Y- ROE-7.50% 52W Range6.70 - 146.16 Perf YTD808.21%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-57.62% Beta0.93
Dividend %- Quick Ratio60.30 Sales past 5Y- Gross Margin- 52W Low824.48% ATR8.92
Employees11 Current Ratio60.30 Sales Q/Q- Oper. Margin- RSI (14)49.51 Volatility16.51% 14.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-179.80% Profit Margin- Rel Volume1.91 Prev Close60.12
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume7.95M Price61.94
Recom2.00 SMA2020.35% SMA50-25.41% SMA20013.38% Volume14,913,746 Change3.03%
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Sep-27-21 05:40AM  
Sep-26-21 12:00PM  
10:09AM  
08:27AM  
Sep-25-21 07:30PM  
11:58AM  
11:14AM  
08:03AM  
Sep-24-21 10:50PM  
07:30PM  
07:07PM  
12:20PM  
11:46AM  
11:45AM  
11:00AM  
10:09AM  
08:40AM  
05:40AM  
Sep-23-21 10:40PM  
08:54PM  
08:44PM  
07:15PM  
07:11PM  
06:21PM  
06:05PM  
05:15PM  
04:30PM  
01:45PM  
01:34PM  
01:00PM  
12:15PM  
11:45AM  
11:00AM  
10:30AM  
10:26AM  
08:45AM  
05:40AM  
Sep-22-21 10:50PM  
09:08PM  
08:17PM  
06:20PM  
04:15PM  
04:08PM  
12:20PM  
12:10PM  
11:16AM  
09:36AM  
08:45AM  
08:30AM  
05:40AM  
Sep-21-21 10:42PM  
07:48PM  
06:19PM  
05:50PM  
05:02PM  
04:36PM  
03:48PM  
03:15PM  
02:45PM  
01:45PM  
01:23PM  
09:15AM  
08:40AM  
05:40AM  
Sep-20-21 10:47PM  
06:18PM  
06:07PM  
05:45PM  
04:40PM  
12:37PM  
12:15PM  
11:00AM  
10:30AM  
09:31AM  
09:30AM  
08:00AM  
05:50AM  
Sep-19-21 11:33PM  
10:21AM  
08:27AM  
Sep-18-21 04:45PM  
09:33AM  
08:03AM  
Sep-17-21 10:00PM  
04:58PM  
04:31PM  
04:16PM  
03:10PM  
02:15PM  
01:25PM  
01:25PM  
01:00PM  
11:35AM  
11:00AM  
09:45AM  
08:55AM  
06:00AM  
Sep-16-21 11:00PM  
05:54PM  
05:50PM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSSIN ROBERT ZDirectorSep 15Option Exercise27.372,80176,6636,710Sep 21 04:01 PM
BARBIER REMIPresident and CEOJul 20Option Exercise20.232,80156,664326,652Jul 20 05:21 PM
BARBIER REMIPresident and CEOMay 27Option Exercise53.5556,0303,000,4061,134,885May 28 04:01 PM
ROBERTSON SANFORDDirectorMar 30Option Exercise40.897,472305,521920,095Mar 31 09:14 PM
FRIEDMANN NADAVChief Medical OfficerMar 17Option Exercise53.5528,0151,500,20392,428Mar 18 04:06 PM
O DONNELL MICHAEL JDirectorMar 16Option Exercise49.004,669228,7819,257Mar 18 03:59 PM